Bristol Myers Squibb Plans 2026 UK Launch of Breakthrough Schizophrenia Drug Cobenfy at $22,500 Annual Price
Key Insights
Bristol Myers Squibb (search) announced plans to launch its schizophrenia (search) treatment Cobenfy in the UK in 2026, pricing it at $1,850 monthly or $22,500 annually to match its U.S. list price.
Cobenfy represents the first approved antipsychotic targeting cholinergic receptors (search) rather than dopamine receptors (search), marking a significant departure from the standard of care for schizophrenia (search) treatment.
The company will submit a marketing authorization application to UK regulators later this year under a fast-track route, while warning it may withdraw if pricing negotiations with NICE and NHS don't adequately recognize the drug's value.
Bristol Myers Squibb (search) announced Monday its intention to launch the breakthrough schizophrenia (search) treatment Cobenfy in the United Kingdom in 2026, with pricing set to match its U.S. list price of $1,850 per month or approximately $22,500 annually. The pharmaceutical giant plans to submit a marketing authorization application to UK medicines regulators later this year under a fast-track approval pathway.
Novel Mechanism of Action
Cobenfy gained U.S. FDA approval last year as the first approved antipsychotic that targets cholinergic receptors (search), representing a significant departure from dopamine receptor-targeting medications that have long served as the standard of care for schizophrenia (search) treatment. This novel mechanism of action positions the drug as a potential game-changer in psychiatric medicine.
Bristol Myers acquired the drug, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics (search). The company estimates that schizophrenia (search) affects approximately 1 in 100 people in the UK, with the mental health disorder causing persistent delusions and hallucinations that significantly impair patients' perception of reality.
Pricing Strategy and Market Access
The company's pricing approach reflects broader industry tensions over drug valuations between the U.S. and European markets. "We agree with the Trump administration that other countries need to pay their fair share," said Adam Lenkowsky, Bristol's chief commercialization officer, referencing ongoing discussions about raising European drug prices to help reduce costs in the United States.
Unlike the U.S. market where pricing is largely determined by market forces, European governments typically negotiate directly with pharmaceutical companies to establish prices for their national healthcare systems. This fundamental difference in pricing mechanisms has created ongoing friction between drugmakers and European health authorities.
Regulatory and Commercial Outlook
Bristol Myers has issued a clear warning regarding market access negotiations with UK health authorities. "Our intention is to work with NICE and NHS to make this medicine available, but we are prepared to make the difficult decision to walk away if they cannot better recognize the value our medicine brings to patients and society," Lenkowsky stated.
The pharmaceutical industry has been increasingly vocal about what it characterizes as Britain's underinvestment in life sciences, particularly criticizing the National Institute for Health and Care Excellence (NICE) system for evaluating and pricing medicines.
Strategic Importance for Bristol Myers
Investors are closely monitoring Bristol's newer products, including Cobenfy and cell therapy Breyanzi, as potential drivers of the company's next growth phase. This focus comes as sales of the company's older blockbuster treatments face natural decline, making successful launches of innovative therapies crucial for maintaining revenue momentum.
The company's commitment to pricing Cobenfy at U.S. levels in the UK market represents a test case for the industry's broader strategy of seeking higher prices in European markets while potentially offering cost savings to American patients.